Strides Pharma Science Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million)
Strides Pharma Science Ltd · Outcome · 30 Oct 2026, 12:13 am
Strides Pharma Science Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) ■ Revenue: 14,297 (+17.1% YoY | +13.0% QoQ) ■ EBITDA: 2,509 (+8.4% YoY | +9.2% QoQ) ■ EBITDA Margin (%): 17.5 (-142 bps YoY | -61 bps QoQ) ■ PAT: 1,308 (+2.6% YoY | -16.6% QoQ) ■ EPS (INR): 14.2 (+2.5% YoY | -16.6% QoQ)
Original exchange filing (PDF)
More announcements from Strides Pharma Science Ltd
- Transcript of Earnings Call pertaining of Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026 · 02 Nov 2026
- Audio Recording of Earnings Call pertaining to unaudited Financial Results for the quarter and half year ended September 30, 2026 · 30 Oct 2026
- Appointment of Mr. Biren Gabhawala (DIN:03091772) as a Non-Executive Independent Director of the Company with effect from November 1, 2026. · 30 Oct 2026
- Allotment of Equity shares pursuant to exercise of Stock Options. · 30 Oct 2026
- Earnings presentation for the quarter and half year ended September 30, 2026. · 30 Oct 2026
- Strides Delivers Strong Performance with Q2FY27 Revenue at Rs. 14.297m, Grew 17% YoY. Ex-US Markets Up 31% YoY; EBITDA Up 8% YoY to Rs. 2,509m, Crossing Rs. 2,500m in a Quarter for the First Time. · 30 Oct 2026
- Financial Results for the quarter and half year ended Sept 30, 2026 · 30 Oct 2026
- Earnings Call to discuss the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026 · 30 Oct 2026
